NeuroScientific Biopharmaceuticals has unveiled positive results from two studies using its stem cell therapy in kidney transplantation. Eight out of 10 patients in a small case series, facing severe organ rejection, retained their donor kidney. A second study showed the treatment was safe and may improve graft function in deceased-donor transplants. The findings have bolstered the company's plans for a wider clinical development in the multibillion-dollar global market.
